TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Incidence of Hypophosphatemia After Treatment With Iron Isomaltoside/Ferric Derisomaltose vs Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria include:~* Subjects diagnosed with IDA, caused by different aetiologies~* Haemoglobin (Hb) ≤ 11 g/dL~* Body weight \> 50 kg~* Serum ferritin (S-ferritin) \< 100 ng/mL~* Estimated glomerular filtration rate (eGFR) ≥ 65 mL/min/1.73 m2~* Serum phosphate (S-phosphate) \> 2.5 mg/dL~* Intolerance or unresponsiveness to oral iron~* Willingness to participate and signing the Informed Consent Form (ICF)~Exclusion Criteria include:~* Acute bleeding \> 500 mL within 72 hours~* Anaemia predominantly caused by factors other than IDA~* Hemochromatosis or other iron storage disorders~* Previous serious hypersensitivity reactions to any IV iron compounds~* Treatment with IV iron within the last 30 days prior to screening~* Treatment with erythropoietin or erythropoietin-stimulation agents~* Red blood cell transfusion, radiotherapy, and/or chemotherapy~* Received an investigational drug within the last 30 days prior to screening~* Planned surgical procedure within the trial period~* Hepatic enzymes \> 3 times upper limit of normal~* Surgery under anaesthetic within the last 30 days prior to screening~* Any non-viral infection within the last 30 days prior to screening~* Alcohol or drug abuse within the past 6 months~* Vitamin D deficiency~* Untreated hyperparathyroidism~* Kidney transplantation~* Active malignant disease, disease-free for less than 5 years~* History of a psychological illness or seizures~* Pregnant or nursing women.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Iron isomaltoside/ferric derisomaltose (Type: EXPERIMENTAL): Administered IV
- Ferric carboxymaltose (Type: ACTIVE_COMPARATOR): Administered IV

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of ALXN1210 in Complement Inhibitor Treatment-Naïve Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female ≥ 12 years of age and weighing ≥ 40 kg at the time of consent.~2. Evidence of thrombotic microangiopathy, including low platelet count, hemolysis (breaking of red blood cells inside of blood vessels), and decreased kidney function.~3. Documented meningococcal vaccination not more than 3 years prior to, or at the time of, initiating study drug. Participants who received a meningococcal vaccine less than 2 weeks before initiating ravulizumab treatment must have received treatment with appropriate prophylactic antibiotics until 2 weeks after vaccination. Participants who had not been vaccinated prior to initiating ravulizumab treatment should have received prophylactic antibiotics prior to and for at least 2 weeks after meningococcal vaccination. Participants \< 18 years of age must have been vaccinated against haemophilus influenzae type b and streptococcus pneumoniae according to national and local vaccination schedule guidelines.~4. Female participants of childbearing potential and male participants with female partners of childbearing potential had to use highly effective contraception starting at screening and continuing until at least 8 months after the last dose of ravulizumab.~Exclusion Criteria:~1. A disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 deficiency (activity \< 5%).~2. Shiga toxin-related hemolytic uremic syndrome.~3. Positive direct Coombs test.~4. Pregnancy or breastfeeding.~5. Identified drug exposure-related hemolytic uremic syndrome (HUS).~6. Bone marrow transplant/hematopoietic stem cell transplant within last 6 months prior to start of Screening.~7. HUS related to known genetic defects of cobalamin C metabolism.~8. Systemic sclerosis (scleroderma), systemic lupus erythematosus, or antiphospholipid antibody positivity or syndrome.~9. Chronic dialysis (defined as dialysis on a regular basis as renal replacement therapy for end-stage kidney disease).

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ravulizumab (Type: EXPERIMENTAL): Participants were administered weight-based doses of ravulizumab every 8 weeks for 26 weeks in the Initial Evaluation Period.~After the Initial Evaluation Period, participants could enter an Extension Period and receive ravulizumab until the product registration or approval (in accordance with country-specific regulations) or for up to 4.5 years, whichever occurs first.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of PRO-155 on Inflammation of the Conjunctival Surface in Subjects With Grade I-III Pterygium vs Placebo.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age of 18 to 90 years.~* Both genders.~* Clinical diagnosis of grade I to III pterygium (temporal, nasal, or bitemporal).~* Possibility of going to the revisions when indicated.~Exclusion Criteria:~* Subjects with topical or systemic medication that interfere decisively in the results of the study; such as topical immunomodulators, NSAIDs, antihistamines, corticosteroids, artificial tears with conservative, vasoconstrictors etc.~* Subjects (female) with active sexual life who do not use a contraceptive method.~* Subjects of the female sex in a pregnant state or who are breastfeeding.~* Subjects of the female sex with pregnancy test in positive urine.~* Positive substance abuse~* Subjects who have participated in any clinical research study in the last 40 days.~* Subjects legally or mentally incapacitated to give their informed consent for their participation in this study.~* Subjects that can not comply with the appointments or with all the requirements of the Protocol.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- PRO-155 (Type: EXPERIMENTAL): Pro-155: 1 drop 2 times a day in the period of vigil in the conjunctival cul-de-sac for 20 days
- Placebo (Type: PLACEBO_COMPARATOR): Placebo 1 drop 2 times a day in the period of vigil in the conjunctival cul-de-sac

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Dapagliflozin on Platelet Function testinG Profiles in Diabetic PatiEnts.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. between 18 and 74 years of age,~2. have stable coronary artery disease and diabetes mellitus, already on DAPT with aspirin and clopidogrel for at least 6 months,~3. not on any physician-prescribed medications or complementary/alternative therapies.~Exclusion Criteria:~1. presence of active internal bleeding or history of bleeding diathesis or clinical findings associated with an increased risk of bleeding,~2. history of ischemic or hemorrhagic stroke, transient ischemic attack, intracranial neoplasm, arteriovenous malformation, or aneurysm,~3. history of clinical and/or hemodynamic instability,~4. within 1 month of placement of a bare-metal stent,~5. within 30 days of coronary artery bypass graft surgery or PCI without a stent placed,~6. planned coronary revascularization,~7. treatment with fibrin-specific fibrinolytic therapy \<24 h or non-fibrin-specific fibrinolytic therapy \<48 h,~8. use of an oral anticoagulation agent or international normalized ratio \>1.5,~9. body weight \<60 kg,~10. age \>75 years,~11. hemoglobin \<10 g/dL,~12. platelet count \<100×106/μL,~13. creatinine \>2 mg/dL,~14. hepatic enzymes \>2.5 times the upper limit of normal,~15. pregnancy and/or lactation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- DAPA Tx (Type: OTHER): This arm will comprise the participants who are administered Dapagliflozin 10mg per oral once daily for 2 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Assess the Efficacy and Safety of Three Doses of PT001 in Japanese Subjects With Moderate to Severe COPD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical history of COPD with a moderate to severe classification~* Current and former smokers with a history of at least 10 pack-years of cigarette smoking.~-Post-bronchodilator FEV1 must be ≥30% and \<80% predicted normal value-~Exclusion Criteria:~* Pregnancy~* Primary asthma diagnosis; Poorly controlled COPD defined as acute worsening of COPD that required treatment with corticosteroids or antibiotics in the 6-week interval prior to Screening or between Screening and Visit 2;~* Clinically significant abnormal ECG~* Other active pulmonary disease such as active tuberculosis, lung cancer, bronchiectasis, sarcoidosis, lung fibrosis, primary pulmonary hypertension, interstitial lung disease, and uncontrolled sleep apnea; Cancer that was not in complete remission for at least 5 years;~* Diagnosis of angle closure glaucoma~* A documented myocardial infarction within 1 year of Screening.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- GP MDI 28.8 micrograms (Type: ACTIVE_COMPARATOR): Glycopyrronium Metered Dose Inhaler 28.8 micrograms
- GP MDI 14.4 micrograms (Type: ACTIVE_COMPARATOR): Glycopyrronium Metered Dose Inhaler 14.4 micrograms
- GP MDI 7.2 micrograms (Type: ACTIVE_COMPARATOR): Glycopyrronium Metered Dose Inhaler 7.2 micrograms
- Placebo MDI (Type: PLACEBO_COMPARATOR): Placebo Inhalation Aerosol

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Controlling Oral Malodor by ClōSYS® Oral Rinse

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Completion of the Informed Consent.~* Must be able to follow verbal/written instructions.~* Between 21 to 65 years of age, male or female.~* Has normal oral interior cheek wall tissues.~* In good general health.~* Should not have any severe or debilitating disease that may impede participation.~* Average organoleptic intensity rating of at \>2.6 but \<4.5 on an intensity scale of 0-5.~Exclusion Criteria:~* Pregnant or nursing.~* Diagnosis of Xerostomia, including medication induced Xerostomia.~* Oral or extraoral piercing that interferes with the clinical assessments in the mouth.~* Fixed or removable oral appliance.~* Advanced periodontal disease or excessive gingival recession.~* Known allergy or sensitivity to study products.~* Unwilling to abstain from all oral hygiene products other than those prescribed for the study.~* Heavy deposits of calculus, either supragingival and/or subgingival.~* History of severe transmittable infectious disease e.g. hepatitis, HIV, tuberculosis.~* Medical or dental condition that would be unduly affected by participation in this study.~* Any other condition that may interfere with the study.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Test-Unflavored Rinse (Type: ACTIVE_COMPARATOR): CloSYS Oral Rinse product containing 0.1% stabilized chlorine dioxide (sodium chlorite) in aqueous solution.
- Test-Flavored Rinse (Type: ACTIVE_COMPARATOR): CloSYS Oral Rinse product containing 0.1% stabilized chlorine dioxide (sodium chlorite) in aqueous solution with mint flavoring.
- Placebo (Type: PLACEBO_COMPARATOR): CloSYS Oral Rinse product (no chlorine dioxide)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pyronaridine - Artesunate (3:1) Versus Mefloquine Plus Artesunate in Plasmodium Falciparum Malaria Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female patients between the ages of 3 and 60 years, inclusive.~* Body weight between 20 kg and 90 kg with no clinical evidence of severe malnutrition.~* Presence of acute uncomplicated P. falciparum mono-infection confirmed by:~  1. Fever, as defined by axillary/tympanic temperature ≥37.5°C or oral/rectal temperature ≥38°C, or documented history of fever in the previous 24 hours and,~ 2. Positive microscopy of P. falciparum with parasite density between 1,000 and 100,000 asexual parasite count/µl of blood~* Written informed consent provided by patient and/or parent/guardian/spouse.~* Ability to swallow oral medication.~Exclusion Criteria:~* Patients with signs and symptoms of severe/complicated malaria requiring parenteral treatment according to the World Health Organization Criteria 2000.~* Mixed Plasmodium infection.~* Severe vomiting or severe diarrhoea.~* Known history or evidence of clinically significant disorders.~* Presence of significant anaemia, as defined by Hb \<8 g/dL.~* Presence of febrile conditions caused by diseases other than malaria.~* Known history of hypersensitivity, allergic or adverse reactions to pyronaridine, mefloquine or artesunate or other artemisinins.~* Use of any other antimalarial agent within 2 weeks prior to start of the study as evidenced by positive urine test.~* Female patients of child-bearing potential must be neither pregnant (as demonstrated by a negative pregnancy test) nor lactating, and must be willing to take measures to not become pregnant during the study period.~* Presence of significant renal or hepatic impairment.~* Receipt of an investigational drug within the past 4 weeks.~* Known active Hepatitis A IgM, Hepatitis B surface antigen or Hepatitis C antibody.~* Known seropositive HIV antibody.~* Previous participation in any clinical study with PA.

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Pyronaridine - artesunate (Type: EXPERIMENTAL): Oral pyronaridine artesunate (180:60mg tablets) once a day for 3 consecutive days (Day 0, 1, and 2). Posology based on body weight ranges.
- Mefloquine plus artesunate (Type: ACTIVE_COMPARATOR): Mefloquine (250mg tablets) plus artesunate (100mg tablets) once a day for 3 consecutive days (Day 0, 1, and 2). Posology based on body weight ranges.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetics and Safety of Posaconazole Tablet in Participants at High Risk for Invasive Fungal Infections (MK-5592-065/P05615)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Body weight \>34 kg (75 lb) and of any race/ethnicity~* Able to swallow oral tablets whole~* Anticipated (likely to develop within 3-5 days) or documented neutropenia due to chemotherapy, chemotherapy for a new diagnosis of acute myelogenous leukemia (AML), or AML in first relapse; myelodysplastic syndromes (MDS) in transformation to AML; allogeneic hematopoietic stem cell transplant (HSCT) participants in the pre-engraftment period or in the post-engraftment period if they are receiving immunosuppressive therapy for graft versus host disease~Exclusion Criteria:~- Female must not be pregnant, must not intend to become pregnant~during the study, and must not be nursing~* History of hypersensitivity to azoles~* Moderate or severe liver dysfunction defined as aspartate aminotransferase (AST) or alanine aminotransferase (ALT) levels greater than three times the upper limit of normal (ULN), AND a total bilirubin level greater than two times the ULN~* Electrocardiogram (ECG) with corrected QTc interval greater than 500 msec~* Posaconazole within 10 days before study enrollment~* Receipt of systemic antifungal therapy within 30 days of study enrollment for reasons other than antifungal prophylaxis~* Evidence of known or suspected invasive or systemic fungal infection at baseline~* Known or suspected history of Gilbert's disease~* Creatinine clearance levels below 30 mL/min

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Posaconazole 200 mg (Type: EXPERIMENTAL): Posaconazole 200 mg (two 100 mg tablets) twice daily (BID) on Day 1 followed by 200 mg (two 100 mg tablets) once daily (QD) for up to 28 days
- Posaconazole 300 mg (Type: EXPERIMENTAL): Posaconazole 300 mg (three 100 mg tablets) BID on Day 1 followed by 300 mg (three 100 mg tablets) QD for up to 28 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Extension Study of Zemaira® i.v. Administration in Subjects With Emphysema Due to alpha1-proteinase Inhibitor Deficiency.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who have completed the 2-year treatment and observation period in the Phase 3/4 Zemaira® CE1226_4001 study (NCT00261833) and are willing to sign informed consent~* Males, and non-pregnant, non-lactating females, whose screening pregnancy test is negative and who are using contraceptive methods deemed reliable by the investigator~Exclusion Criteria:~* Individuals residing in the US~* Current evidence of alcohol abuse or abuse of drugs such as barbiturates, benzodiazepines, amphetamines, cocaine, opioids, and cannabinoids~* History of allergy, anaphylactic reaction, or severe systemic response to human plasma derived products, or known mannitol hypersensitivity, or history of prior adverse reaction to mannitol~* Current tobacco smoker (smoking must be discontinued for at least 6 months prior to study participation)~* Conditions or behaviors that interfere with attending scheduled study visits in the opinion of the investigator~* History of non-compliance~* Administration of any other experimental new drug or participation in an investigation of a marketed product~* Inability to perform necessary study procedures

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Zemaira® (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Low Bone Density in Cystic Fibrosis.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age 2-30 years~* clinically stable condition~* regular menses in females~* low Bone Mineral Apparent Density for age (defined as BMAD Z-score ≤-2.0 if age ≤18 years or ≤-2.5 if age \>18 years).~Exclusion Criteria:~* two or more episodes of hypercalcemia and/or hypercalciuria~* contraindications to 25-OH vitamin D or alendronate treatment~* recent transplantation~* other diseases or medications (glucocorticoids excepted) associated with bone loss.

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 30 Years
- Healthy Volunteers: f

Study Arms:
- Alendronate (Type: ACTIVE_COMPARATOR): 128 subjects participated in the study's Phase 2 (1-year double-blind, randomized, placebo-controlled, parallel group study).~65 subjects were randomized to this arm. Oral alendronate dose: 5 mg/day, if body weight ≤25 kg; 10 mg/day, if body weight \>25 kg.
- Placebo (Type: PLACEBO_COMPARATOR): 128 subjects participated in the study's Phase 2 (1-year double-blind, randomized, placebo-controlled, parallel group study).~63 subjects were randomized to this arm. Oral placebo (inactive pills).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Monthly Intravenous C.E.R.A. (Mircera) in Hemodialysis Participants With Chronic Renal Anemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Chronic renal anemia;~* Continuous intravenous maintenance erythropoietin stimulating agent (ESA) treatment during previous month;~* Regular long term hemodialysis therapy with the same mode of dialysis for \>=3 months.~Exclusion Criteria:~* Transfusion of red blood cells during previous 2 months;~* Significant acute or chronic bleeding, such as overt gastrointestinal bleeding;~* Active malignant disease (except non-melanoma skin cancer).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- C.E.R.A. (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete